BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Delinia fits Celgene to a ‘T’ in potential $775M acquisition
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Delinia fits Celgene to a ‘T’ in potential $775M acquisition
Jan. 27, 2017
By
Marie Powers
No Comments
Startup Delinia Inc. hitched its potentially transformative immune regulatory wagon to the Celgene Corp. train, agreeing to a potential $775 million acquisition the same day Celgene reported its fourth-quarter and full-year 2016 financial results.
BioWorld